Do intravitreal Ranibizumab injections for wet age-related macular degeneration affect the vitreomacular interface?

S. Sreekanth, Jonathan Gibson

Research output: Contribution to conferenceAbstract

Abstract

Presentation

Abstract - Purpose:Serial intravitreal ranibizumab injections are the main treatment for wet age- related macular degeneration (AMD), and patients are monitored by optical coherence tomography (OCT). Our objective in conducting this study is to determine whether serial intravitreal injections of ranibizumab in eyes with wet AMD alter the vitreo-macular interface (VMI)

Methods - Using a Topcon Spectral Domain OCT, we performed a prospective, observational study of 87 eyes of 82 consecutive patients undergoing treatment with intravitreal ranibizumab for wet AMD, with each patient followed up for a minimum of 6 months. The mean number of intravitreal ranibizumab injections was 4.28, range 3-6. Using macular OCT scans, the area of VMI was closely examined, for vitreo-macular adhesion (VMA), defined as perifoveal posterior vitreous detachment (PVD) with posterior vitreous attached to fovea. Any OCT separation of posterior vitreous face was observed and measured, every month for 6 months.

Results - There was no change in the OCT appearance or measurement of VM interface in 80 eyes (92%). VM adhesion, defined on OCT as when the posterior hyaloid line is attached to inner foveal surface and dettached perifoveally, was identified in 7 out of 87 treated eyes (8%) .Of these 7 eyes, 1 eye developed complete PVD following three injections, 1 eye developed partial PVD and the remaining 5 eyes had no significant change in VM adhesion.

Conclusions - To our knowledge this is the first study that has examined the VM interface following serial ranibizumab injections for wet AMD. This small pilot study suggests that most cases undergoing ranibizumab therapy suffer no disturbance to VM interface.
Original languageEnglish
Publication statusPublished - 11 Apr 2010
EventArvo 2010 - Fort Lauderdale, United States
Duration: 2 May 20106 May 2010

Conference

ConferenceArvo 2010
CountryUnited States
CityFort Lauderdale
Period2/05/106/05/10

Fingerprint

Intravitreal Injections
Macular Degeneration
Optical Coherence Tomography
Vitreous Detachment
Injections
Ranibizumab
Observational Studies
Therapeutics
Prospective Studies

Keywords

  • age-related macular degeneration
  • injection
  • vitreous

Cite this

Sreekanth, S., & Gibson, J. (2010). Do intravitreal Ranibizumab injections for wet age-related macular degeneration affect the vitreomacular interface?. Abstract from Arvo 2010, Fort Lauderdale, United States.
Sreekanth, S. ; Gibson, Jonathan. / Do intravitreal Ranibizumab injections for wet age-related macular degeneration affect the vitreomacular interface?. Abstract from Arvo 2010, Fort Lauderdale, United States.
@conference{73af6677c42a4097b094ba6cff399232,
title = "Do intravitreal Ranibizumab injections for wet age-related macular degeneration affect the vitreomacular interface?",
abstract = "PresentationAbstract - Purpose:Serial intravitreal ranibizumab injections are the main treatment for wet age- related macular degeneration (AMD), and patients are monitored by optical coherence tomography (OCT). Our objective in conducting this study is to determine whether serial intravitreal injections of ranibizumab in eyes with wet AMD alter the vitreo-macular interface (VMI)Methods - Using a Topcon Spectral Domain OCT, we performed a prospective, observational study of 87 eyes of 82 consecutive patients undergoing treatment with intravitreal ranibizumab for wet AMD, with each patient followed up for a minimum of 6 months. The mean number of intravitreal ranibizumab injections was 4.28, range 3-6. Using macular OCT scans, the area of VMI was closely examined, for vitreo-macular adhesion (VMA), defined as perifoveal posterior vitreous detachment (PVD) with posterior vitreous attached to fovea. Any OCT separation of posterior vitreous face was observed and measured, every month for 6 months.Results - There was no change in the OCT appearance or measurement of VM interface in 80 eyes (92{\%}). VM adhesion, defined on OCT as when the posterior hyaloid line is attached to inner foveal surface and dettached perifoveally, was identified in 7 out of 87 treated eyes (8{\%}) .Of these 7 eyes, 1 eye developed complete PVD following three injections, 1 eye developed partial PVD and the remaining 5 eyes had no significant change in VM adhesion.Conclusions - To our knowledge this is the first study that has examined the VM interface following serial ranibizumab injections for wet AMD. This small pilot study suggests that most cases undergoing ranibizumab therapy suffer no disturbance to VM interface.",
keywords = "age-related macular degeneration, injection, vitreous",
author = "S. Sreekanth and Jonathan Gibson",
year = "2010",
month = "4",
day = "11",
language = "English",
note = "Arvo 2010 ; Conference date: 02-05-2010 Through 06-05-2010",

}

Sreekanth, S & Gibson, J 2010, 'Do intravitreal Ranibizumab injections for wet age-related macular degeneration affect the vitreomacular interface?' Arvo 2010, Fort Lauderdale, United States, 2/05/10 - 6/05/10, .

Do intravitreal Ranibizumab injections for wet age-related macular degeneration affect the vitreomacular interface? / Sreekanth, S.; Gibson, Jonathan.

2010. Abstract from Arvo 2010, Fort Lauderdale, United States.

Research output: Contribution to conferenceAbstract

TY - CONF

T1 - Do intravitreal Ranibizumab injections for wet age-related macular degeneration affect the vitreomacular interface?

AU - Sreekanth, S.

AU - Gibson, Jonathan

PY - 2010/4/11

Y1 - 2010/4/11

N2 - PresentationAbstract - Purpose:Serial intravitreal ranibizumab injections are the main treatment for wet age- related macular degeneration (AMD), and patients are monitored by optical coherence tomography (OCT). Our objective in conducting this study is to determine whether serial intravitreal injections of ranibizumab in eyes with wet AMD alter the vitreo-macular interface (VMI)Methods - Using a Topcon Spectral Domain OCT, we performed a prospective, observational study of 87 eyes of 82 consecutive patients undergoing treatment with intravitreal ranibizumab for wet AMD, with each patient followed up for a minimum of 6 months. The mean number of intravitreal ranibizumab injections was 4.28, range 3-6. Using macular OCT scans, the area of VMI was closely examined, for vitreo-macular adhesion (VMA), defined as perifoveal posterior vitreous detachment (PVD) with posterior vitreous attached to fovea. Any OCT separation of posterior vitreous face was observed and measured, every month for 6 months.Results - There was no change in the OCT appearance or measurement of VM interface in 80 eyes (92%). VM adhesion, defined on OCT as when the posterior hyaloid line is attached to inner foveal surface and dettached perifoveally, was identified in 7 out of 87 treated eyes (8%) .Of these 7 eyes, 1 eye developed complete PVD following three injections, 1 eye developed partial PVD and the remaining 5 eyes had no significant change in VM adhesion.Conclusions - To our knowledge this is the first study that has examined the VM interface following serial ranibizumab injections for wet AMD. This small pilot study suggests that most cases undergoing ranibizumab therapy suffer no disturbance to VM interface.

AB - PresentationAbstract - Purpose:Serial intravitreal ranibizumab injections are the main treatment for wet age- related macular degeneration (AMD), and patients are monitored by optical coherence tomography (OCT). Our objective in conducting this study is to determine whether serial intravitreal injections of ranibizumab in eyes with wet AMD alter the vitreo-macular interface (VMI)Methods - Using a Topcon Spectral Domain OCT, we performed a prospective, observational study of 87 eyes of 82 consecutive patients undergoing treatment with intravitreal ranibizumab for wet AMD, with each patient followed up for a minimum of 6 months. The mean number of intravitreal ranibizumab injections was 4.28, range 3-6. Using macular OCT scans, the area of VMI was closely examined, for vitreo-macular adhesion (VMA), defined as perifoveal posterior vitreous detachment (PVD) with posterior vitreous attached to fovea. Any OCT separation of posterior vitreous face was observed and measured, every month for 6 months.Results - There was no change in the OCT appearance or measurement of VM interface in 80 eyes (92%). VM adhesion, defined on OCT as when the posterior hyaloid line is attached to inner foveal surface and dettached perifoveally, was identified in 7 out of 87 treated eyes (8%) .Of these 7 eyes, 1 eye developed complete PVD following three injections, 1 eye developed partial PVD and the remaining 5 eyes had no significant change in VM adhesion.Conclusions - To our knowledge this is the first study that has examined the VM interface following serial ranibizumab injections for wet AMD. This small pilot study suggests that most cases undergoing ranibizumab therapy suffer no disturbance to VM interface.

KW - age-related macular degeneration

KW - injection

KW - vitreous

UR - http://www.abstractsonline.com/plan/ViewAbstract.aspx?mID=2511&sKey=5c50994a-c3db-418b-b479-ad8b90c64202&cKey=7bd2707c-a0df-40da-b417-5cfc696e0400&mKey=%7b1EA90E66-C548-49E0-9F05-30DA7938D511%7d

M3 - Abstract

ER -

Sreekanth S, Gibson J. Do intravitreal Ranibizumab injections for wet age-related macular degeneration affect the vitreomacular interface?. 2010. Abstract from Arvo 2010, Fort Lauderdale, United States.